Imaging of neuroendocrine tumors

Bibliography

• Yao JC, Hassan M, Phan A, One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72
   PubMed Web of Science ®Google Scholar
• Modlin IM, Kidd M, Latich I, Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717-51
   PubMed Web of Science ®Google Scholar
• de Herder WW, Kwekkeboom DJ, Valkema R, Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest 2005;28(11 Suppl):132-6
   PubMedGoogle Scholar
• Gabriel M, Decristoforo C, Kendler D, 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-18
   PubMed Web of Science ®Google Scholar
• Srirajaskanthan R, Kayani I, Quigley AM, The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010;51:875-82
   PubMed Web of Science ®Google Scholar
• Frilling A, Sotiropoulos GC, Radtke A, The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 2010;252:850-6
   PubMed Web of Science ®Google Scholar
• Naswa N, Sharma P, Kumar A, Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol 2011;197(5):1221-8
   PubMed Web of Science ®Google Scholar
• Ambrosini V, Campana D, Bodei L, 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669-73
   PubMed Web of Science ®Google Scholar
• Delle Fave G, Kwekkeboom DJ, Van Cutsem E, ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology 2012;95:74-87
   PubMed Web of Science ®Google Scholar
• Sundin A, Vullierme MP, Kaltsas G, Plockinger U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations. Neuroendocrinology 2009;90:167-83
   PubMed Web of Science ®Google Scholar
• Anderson MA, Carpenter S, Thompson NW, Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000;95:2271-7
   PubMed Web of Science ®Google Scholar
• Rickes S, Monkemuller K, Malfertheiner P. Contrast-enhanced ultrasound in the diagnosis of pancreatic tumors. JOP 2006;7:584-92
   PubMedGoogle Scholar
• Binderup T, Knigge U, Loft A, Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 2010;51:704-12
   PubMed Web of Science ®Google Scholar
• Cwikła JB, Buscombe JR, Caplin ME, Diagnostic imaging of carcinoid metastases to the abdomen and pelvis. Med Sci Monit 2004;10(Suppl 3):9-16
   PubMedGoogle Scholar
• Caplin M, Sundin A, Nillson O, ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 2012;95:88-97
   PubMed Web of Science ®Google Scholar
• Hohmann J, Albrecht T, Oldenburg A, Liver metastases in cancer: detection with contrast-enhanced ultrasonography. Abdom Imaging 2004;29:669-81
   PubMed Web of Science ®Google Scholar
• Dromain C, de Baere T, Lumbroso J, Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005;23:70-8
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen ZE, Yaghmai V, Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics. J Magn Reson Imaging 2011;33:1071-9
   PubMed Web of Science ®Google Scholar
• Liapi E, Geschwind JF, Vossen JA, Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol 2008;190:67-73
   PubMed Web of Science ®Google Scholar
• Brenner R, Metens T, Bali M, Pancreatic neuroendocrine tumor: Added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection. Eur J Radiol 2012 [Epub ahead of print]
   PubMedGoogle Scholar
• Sundin A, Eriksson B, Bergstrom B, Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. Nucl Med Biol 2000;27:33-41
   PubMed Web of Science ®Google Scholar
• Orlefors H, Sundin A, Garske U, Whole-body 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors - comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392-400
   PubMed Web of Science ®Google Scholar
• Koopmans KP, Neels OC, Kema IP, Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008;26:1489-95
   PubMed Web of Science ®Google Scholar